iTeos Therapeutics ITOS 深 滬
已收盤 08-01 16:00:00 美东时间
10.09
-0.050
-0.49%
華盛通- 最 高10.15
- 今 開10.15
- 成交量 154.28万股
- 最 低 10.09
- 昨 收 10.14
- 總市值 3.86亿
- 52周最高 18.13
- 市盈率 靜 --
- 換手率 4.03%
- 52周最低 4.80
- 委 比 24.79%
- 總股本 3827.38万
- 歷史最高 52.43
- 量 比 1.72
- 振 幅 0.59%
- 歷史最低 4.80
- 每 手 1
- 風險率 2.88%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Concentra Biosciences To Acquire iTeos For $10.047 In Cash Per Share Plus One Non-Transferable Contingent Value Right
iTeos Therapeutics, Inc. ("iTeos") (NASDAQ:ITOS) today announced that it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC ("Concentra") will acquire iTeos for $10.047 in cash per share of
07-21 19:30
iTeos Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $10.047 in Cash per Share Plus a Contingent Value Right
iTeos Therapeutics has entered into a definitive merger agreement with Concentra Biosciences, under which Concentra will acquire iTeos for $10.047 per share of common stock, plus a contingent value right (CVR). The iTeos board unanimously approved the agreement, deeming it in the best interest of all stockholders. The transaction will commence with a tender offer by August 1, 2025, subject to conditions including shareholder majority and $475 mil...
07-21 11:29
Tim Van Hauwermeiren Resigns from iTeos Board
iTeos Therapeutics ( ($ITOS) ) has shared an update. On June 1, 2025, Tim Van H...
06-06 05:51
美股牛股 | 生物制药公司SPRO飙涨244%，尿路感染药物3期试验取得成功
生物制药公司SPRO飙涨244%，尿路感染药物3期试验取得成功；Joby Aviation大涨28%，获丰田汽车2.5亿美元战略投资>>
05-29 19:18
美股大行评级 | 拼多多遭多家大行下调评级！Redburn Atlantic首予博通"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1134767544930545665.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持AnaptysBio(ANAB)"买入"评级，目标价从54美元升至90美元</p> <p>• Canaccord Genuity：维持Bridger Aerospace Gr(BAER)"买入"评
05-29 09:53
iTeos Therapeutics Announces Strategic Wind Down Plan
iTeos Therapeutics ( ($ITOS) ) has issued an update. On May 28, 2025, iTeos The...
05-28 20:58
iTeos surges on plans to end operations
iTeos Therapeutics (NASDAQ:ITOS) added ~25% in the premarket on Wednesday after the immuno-oncology drug developer announced plans to wind down operations as an outcome of a strategic review aimed at ...
05-28 20:53
iTeos Therapeutics Announces Strategic Decision To Wind Down Clinical And Operational Activities Following Termination Of Belrestotug Program And GSK Collaboration, Anticipating $21.8M–$24.7M Severance And $11.1M Program Wind-Down Costs, With Full Wind-Down Expected By Q3 2025
On May 28, 2025, iTeos Therapeutics, Inc. (the "Company") announced its intention to wind down its clinical and operational activities. The action was taken as part of the Company's review of strategic alternatives to
05-28 20:49
iTeos Therapeutics Announces Its Intention to Wind Down Operations
iTeos Therapeutics intends to wind down its operations as part of a strategic review to maximize shareholder value. The company will focus on leveraging its cash balance and exploring potential asset sales, including EOS-984, EOS-215, and a preclinical obesity program targeting ENT1.
05-28 12:30
美股大行评级 | 潜在涨幅1281.22%！Cabaletta Bio获Guggenheim升目标价至25美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130057143861719040.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Cabaletta Bio(CABA)"买入"评级，目标价从23美元升至25美元</p> <p>• 瑞穗：维持Tectonic Therapeutic(TECX)"跑赢大市"评级，目标价从51美元
05-16 08:43
